An Open-label, Parallel-Group Study to Evaluate the Pharmacokinetics of Lemborexant and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2018
At a glance
- Drugs Lemborexant (Primary)
- Indications Circadian rhythm sleep disorders; Insomnia
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 05 Sep 2018 Status changed from recruiting to completed.
- 19 Jul 2018 Planned End Date changed from 30 Mar 2018 to 16 Jul 2018.
- 19 Jul 2018 Planned primary completion date changed from 30 Mar 2018 to 16 Jul 2018.